Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

TSPAN1: A Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance

  • Mir Perez, Cristina
  • Carballo Perich, Laia
  • Castellví Vives, Josep
  • Lorente Guerrero, Juan
  • Benavente Norza, Sergio
  • Lleonart Pajarin, Matilde
  • Temprana Salvador, Jordi
  • Garcia Mayea, Yoelsis
Apoptosi; Cèl·lules mare del càncer; Resistència, Apoptosis; Células madre cancerosas; Resistencia, Apoptosis; Cancer stem cells; Resistance, Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial–mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII): PI15/01262 (M.E.LL.) PI19/00560 (J.M.G.-P.) and CP03/00101 (M.E.L.), CIBERONC (CB16/12/00390 to J.P.R.), Ayudas a Grupos PCTI Principado de Asturias (IDI2018/155 to J.P.R.), co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR (M.E.L.). Y.G.-M. and C.M. were granted by the VHIR and iP-FIS (ISCIII) fellowships respectively.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Distinct Expression and Clinical Significance of Zinc Finger AN-1-Type Containing 4 in Oral Squamous Cell Carcinomas

  • Suárez Canto, Julián
  • Suárez Sánchez, Faustino
  • Domínguez Iglesias, Francisco
  • Hernández Vallejo, Gonzalo
  • García Pedrero, Juana
  • De Vicente, Juan
Zinc finger AN1-type containing 4 (ZFAND4) has emerged as a promising prognostic marker and predictor of metastasis for patients with oral squamous cell carcinoma (OSCC). However, further validation is fundamental before clinical implementation. Hence, this study evaluated the expression pattern of ZFAND4 protein expression by immunohistochemistry using an independent cohort of 125 patients with OSCC, and correlations with the clinicopathologic parameters and disease outcome. Remarkably, ZFAND4 expression, while negligible in normal epithelium, exhibited two distinct expression patterns in tumors that did not overlap. A gross granular staining was characteristic of the undifferentiated cells at the invasive front of tumors, whereas the most differentiated cells located at the center of the tumor nests showed diffuse non-granular staining. ZFAND4 staining was higher in undifferentiated than in differentiated areas of tumors. High ZFAND4 expression in differentiated cells was significantly associated to well-differentiated (p = 0.04) and non-recurrent tumors (p = 0.04), whereas ZFAND4 expression in undifferentiated cells correlated with tumor location (p = 0.005). No correlations between the ZFAND4 expression and patient survival were found. These data question the clinical relevance of ZFAND4 expression as a prognostic biomarker in OSCC, and also reveal distinct ZFAND4 expression patterns depending on the differentiation areas of tumors that should be evaluated separately.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TSPAN1, a Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance

  • Garcia Mayea, Yoelsis|||0000-0002-9395-7471
  • Mir Pérez, Cristina|||0000-0003-3137-6521
  • Carballo, Laia
  • Castellvi, Josep|||0000-0001-5745-9996
  • Temprana-Salvador, Jordi|||0000-0001-9516-1680
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
  • Benavente, Sergi|||0000-0002-2700-3522
  • García-Pedrero, Juana María|||0000-0002-5891-9488
  • Allonca, Eva|||0000-0002-2532-5421
  • Rodrigo, Juan Pablo|||0000-0003-3063-0890
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial-mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neutrophil to Lymphocyte Ratio in Oropharyngeal Squamous Cell Carcinoma, A Systematic Review and Meta-Analysis

  • Rodrigo, Juan Pablo|||0000-0003-3063-0890
  • Sánchez-Canteli, Mario|||0000-0003-0343-0041
  • Triantafyllou, Asterios
  • de Bree, Remco|||0000-0001-7128-5814
  • Mäkitie, Antti A.|||0000-0002-0451-2404
  • Franchi, Alessandro|||0000-0002-1332-5838
  • Hellquist, Henrik
  • Saba, Nabil F.|||0000-0003-4972-1477
  • Stenman, Göran|||0000-0003-1017-7363
  • Takes, Robert P.
  • Valero Mayor, Cristina|||0000-0003-3397-2888
  • Zidar, Nina|||0000-0001-6866-3220
  • Ferlito, Alfio|||0000-0002-8247-8002
Neutrophil-to-lymphocyte ratio (NLR) in peripheral blood samples has been associated with prognosis in several cancers, including head and neck cancer, but in oropharyngeal carcinomas its prognostic value, especially in relation to human papillomavirus (HPV) infection, has been little studied. This meta-analysis, including studies on the prognostic value of NLR in oropharyngeal carcinoma, shows that an elevated pretreatment NLR is associated with a worse prognosis in oropharyngeal cancer, regardless of the type of treatment performed, but this prognostic value appears to be specific to HPV-positive oropharyngeal carcinomas. NLR could be used as an affordable prognostic marker in this type of cancer. Neutrophil-to-lymphocyte ratio (NLR) has been associated with survival in various cancers, including head and neck cancer. However, there is limited information on its role in oropharyngeal squamous cell carcinomas (OPSCC) according to HPV status. This prompted the present meta-analysis. Studies were selected when the prognostic value of NLR prior to treatment was evaluated in OPSCC patients, the cutoff value of NLR was available, and the prognostic value of NLR was evaluated by time-to-event survival analysis. A total of 14 out of 492 articles, including 7647 patients, were analyzed. The results showed a worse prognosis for the patients with a high NLR: The combined hazard ratios (HR) for overall survival (OS) in patients with an elevated NLR was 1.56 (95% confidence interval (CI) 1.21-2.02; p = 0.0006), for disease-free survival was 1.52 (95% CI 1.34-1.73; p < 0.00001), and for recurrence-free survival was 1.86 (95% CI 1.50-2.30; p < 0.00001). This worse prognosis of high NLR was exclusive of HPV-positive patients: HR for OS in the HPV-positive subgroup was 4.05 (95% CI 1.90-8.62 (p = 0.0003), and in the HPV-negative subgroup 0.92 (95% CI 0.47-1.80; p = 0.82). The prognosis of NLR was not influenced by treatment: The HR for OS for patients treated with radiotherapy/chemoradiotherapy (RT/CRT) was 1.48 (95% CI 1.09-2.01; p = 0.01), and for patients treated with surgery (±RT/CRT) was 1.72 (95% CI 1.08-2.72; p = 0.02). In conclusion, an elevated NLR relates to worse outcomes in patients with HPV-positive OPSCC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Novel Role for Nanog As An Early Cancer Risk Marker in Patients with Laryngeal Precancerous Lesions

  • Rodrigo, Juan P.
  • Villaronga, M. Ángeles
  • Menéndez, Sofía T.
  • Hermida-Prado, Francisco
  • Quer, Miquel|||0000-0003-2563-6729
  • Vilaseca, Isabel|||0000-0003-4399-5522
  • Allonca, Eva|||0000-0002-2532-5421
  • Pedregal Mallo, Daniel
  • Astudillo, Aurora
  • García-Pedrero, Juana María|||0000-0002-5891-9488
NANOG is a master regulator of embryonic stem cell pluripotency, found to be frequently aberrantly expressed in a variety of cancers, including laryngeal carcinomas. This study investigates for the first time the role of NANOG expression in early stages of laryngeal tumourigenesis and its potential utility as cancer risk marker. NANOG protein expression was evaluated by immunohistochemistry using two large independent cohorts of patients with laryngeal precancerous lesions, and correlated with clinicopathological parameters and laryngeal cancer risk. NANOG expression was detected by immunohistochemistry in 49 (60%) of 82 laryngeal dysplasias, whereas expression was negligible in patient-matched normal epithelia. Strong NANOG expression was found in 22 (27%) lesions and was established as cut-off point, showing the most robust association with laryngeal cancer risk (P = 0.003) superior to the histological classification (P = 0.320) the current gold standard in the clinical practice. Similar trends were obtained using a multicenter validation cohort of 86 patients with laryngeal dysplasia. Our findings uncover a novel role for NANOG expression in laryngeal tumourigenesis, and its unprecedented application as biomarker for cancer risk assessment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling

  • Estupiñán, Óscar
  • Rey, Verónica
  • Tornín, Juan
  • Murillo, Dzohara
  • Gallego, Borja
  • Huergo, Carmen
  • Blanco-Lorenzo, Verónica
  • González Meana, M. Victoria|||0000-0001-9565-4899
  • Rodríguez, Aida
  • Moris, Francisco
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Ayllon, Veronica
  • Ramos-Mejía, Verónica|||0000-0002-8013-4273
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Rodríguez, René|||0000-0002-0768-7306
Osteosarcomas are frequently associated to a poor prognosis and a modest response to current treatments. EC-8042 is a well-tolerated mithramycin analog that has demonstrated an efficient ability to eliminate tumor cells, including cancer stem cell subpopulations (CSC), in sarcomas. In transcriptomic and protein expression analyses, we identified NOTCH1 signaling as one of the main pro-stemness pathways repressed by EC-8042 in osteosarcomas. Overexpression of NOTCH-1 resulted in a reduced anti-tumor effect of EC-8042 in CSC-enriched 3D tumorspheres cultures. On the other hand, the depletion of the NOTCH-1 downstream target HES-1 was able to enhance the action of EC-8042 on CSCs. Moreover, HES1 depleted cells failed to recover after treatment withdrawal and showed reduced tumor growth potential in vivo. In contrast, mice xenografted with NOTCH1-overexpressing cells responded worse than parental cells to EC-8042. Finally, we found that active NOTCH1 levels in sarcoma patients was associated to advanced disease and lower survival. Overall, these data highlight the relevant role that NOTCH1 signaling plays in mediating stemness in osteosarcoma. Moreover, we demonstrate that EC-8042 is powerful inhibitor of NOTCH signaling and that the anti-CSC activity of this mithramycin analog highly rely on its ability to repress this pathway.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

TSPAN1: A Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance

  • Mir Perez, Cristina
  • Carballo Perich, Laia
  • Castellví Vives, Josep
  • Lorente Guerrero, Juan
  • Benavente Norza, Sergio
  • Lleonart Pajarin, Matilde
  • Temprana Salvador, Jordi
  • Garcia Mayea, Yoelsis
Apoptosi; Cèl·lules mare del càncer; Resistència, Apoptosis; Células madre cancerosas; Resistencia, Apoptosis; Cancer stem cells; Resistance, Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial–mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII): PI15/01262 (M.E.LL.) PI19/00560 (J.M.G.-P.) and CP03/00101 (M.E.L.), CIBERONC (CB16/12/00390 to J.P.R.), Ayudas a Grupos PCTI Principado de Asturias (IDI2018/155 to J.P.R.), co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR (M.E.L.). Y.G.-M. and C.M. were granted by the VHIR and iP-FIS (ISCIII) fellowships respectively.